About-cancer / kurapwa / kiriniki-miedzo / chirwere / merkel-cell / kurapwa

Kurapa Kliniki Miedzo yeMerkel Cell Cancer

Kliniki miedzo ndeyekutsvagisa zvidzidzo zvinosanganisira vanhu. Iwo makiriniki ekuedzwa pane ino runyorwa ndeyeMerkel cell cancer kurapwa Yese miedzo pane irondedzero inotsigirwa neNCI.

Ruzivo rweNCI rwekutanga nezve zviedzo zvemakiriniki zvinotsanangura mhando nezvikamu zvemiyedzo uye maitirwo azvo. Kliniki miedzo inotarisa nzira nyowani dzekudzivirira, kuona, kana kubata chirwere. Iwe ungangoda kufunga nezve kutora chikamu mukutora kiriniki. Taura nachiremba wako kuti akubatsire kusarudza kana imwe yakakunakira iwe.

Miedzo 1-25 ye32 1 2 Inotevera>

Pembrolizumab Inofananidzwa neyakajairwa Yekutarisirwa Kucherekedza Mukurapa Varwere vane Zvakakwana Resected Stage I-III Merkel Cell Cancer

Ichi chikamu chechitatu cheyedzo inoongorora mashandiro anoita pembrolizumab zvichienzaniswa neyakajairwa yekutariswa kwekurapa varwere vane danho I-III Merkel kenza yemaseru iyo yakabviswa zvachose nekuvhiya (resected) Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Nzvimbo: 286 nzvimbo

Pembrolizumab ine kana isina Stereotactic Muviri Radiation Therapy Mukurapa Varwere vane Advanced kana Metastatic Merkel Cell Cancer

Ichi chisinganzwisisike chikamu chechipiri cheyedzo yekuongorora kuti pembrolizumab ine kana isina stereotactic muviri radiation radiation inoshanda pakurapa varwere vane Merkel cell cancer yakapararira kune dzimwe nzvimbo mumuviri. Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Stereotactic muviri radiation kurapwa inoshandisa yakakosha michina kumisikidza murwere uye kuendesa radiation kune mamota ane akakwana kunyatsoita. Iyi nzira inogona kuuraya tumarara maseru ane mashoma masosi pane ipfupi nguva uye anokonzeresa kukuvara kudiki kune chaiwo tishu. Kupa pembrolizumab ne stereotactic muviri radiation radiation inogona kushanda zvirinani pakurapa varwere vane Merkel cell cancer.

Nzvimbo: 246 nzvimbo

An Investigational Immuno-therapy Kudzidza Kuongorora Kudzivirirwa uye Kubudirira kweNivolumab, uye Nivolumab Combination Therapy muVirusi-inosangana neTumors.

Chinangwa chechidzidzo ichi kuongorora kuchengetedzeka uye kushanda kwe nivolumab, uye nivolumab mubatanidzwa kurapwa, kurapa varwere vane hutachiona-hunosangana nemota. Humwe hutachiona hwave kuzivikanwa kuti hunoita basa mukuumbwa kwechimiro uye kukura. Chidzidzo ichi chichaongorora mhedzisiro yemishonga yekudzidza, muvarwere vane mhando dzinotevera dzemamota: - Anal canal cancer - Haisisiri kunyora rudzi urwu rwechirwere - Cancer cancer - Epstein Barr Virus (EBV) yakanaka gastric cancer - Haisisiri kunyora izvi mhando yemota - Merkel Cell Cancer - Kenza yepenile-Haisisiri kunyora rudzi urwu rwegomarara - Vaginal uye gomarara revhu-Haisisiri kunyora rudzi urwu rwebundu - Nasopharyngeal Cancer - Haisisiri kunyoresa rudzi urwu rwemota - Musoro uye Neck Cancer - Haisisiri kunyorera rudzi urwu bundu

Nzvimbo: 10 nzvimbo

Ichi Chidzidzo Chinoongorora KRT-232, Novel Oral Mudiki Molecule Inhibitor ye MDM2, yekurapwa kwevarwere vane (p53WT) Merkel Cell Carcinoma Vakakundikana Anti-PD-1 / PD-L1 Immunotherapy

Ichi chidzidzo chinoongorora KRT-232, inoverengeka yemumuromo madiki mamorekuru inhibitor ye MDM2, yekurapa varwere vane Merkel Cell Carcinoma (MCC) vakakundikana kurapwa neinodarika imwe anti-PD-1 kana anti-PD-L1 immunotherapy. Kuvhiringidza kweMDCM2 inoverengeka mashandiro ekuita muMCC. Ichi chidzidzo chidimbu 2, Open-Label, Imwe-Arm Chidzidzo cheKRT-232 muvarwere vane p53 Wild-Type (p53WT) Merkel Cell Carcinoma

Nzvimbo: 11 nzvimbo

Adjuvant Avelumab muMerkel Cell Cancer

Ichi chisinganzwisisike chikamu chechitatu cheyedzo yekuongorora mashandisiro anoita avelumab pakurapa varwere vane Merkel kenza yemasero iyo yakapararira kune lymph node uye vakavhiyiwa pamwe kana vasina radiation radiation. MaMonoclonal antibodies, senge avelumab, anogona kukurudzira immune system uye kupindira kugona kwesimba remarara kukura nekupararira.

Nzvimbo: 10 nzvimbo

QUILT-3.055: Chidzidzo cheALT-803 muKusanganiswa nePD-1 / PD-L1 Checkpoint Inhibitor muvarwere Vane Kenza Yakawedzera.

Ichi chikamu chechipiri IIb, ruoko-rwumwe chete, multicohort, yakavhurika-mavara multicenter kudzidza ALT-803 pamwe chete neyakagamuchirwa FDA-PD / 1-PD-L1 yekutarisa inhibititor mune varwere vane kenza dzepamberi avo vafambira mberi zvichitevera mhinduro yekutanga kurapwa ne PD-1 / PD-L1 chekutarisa inhibitor kurapa. Vese varwere vanozogamuchira musanganiswa kurapwa kwePD-1 / PD-L1 cheki yekutarisa inhibitor pamwe ALT-803 kusvika anosvika gumi nematanhatu macircule. Kutenderera kwega kwega vhiki nhanhatu pakureba. Varwere vese vanogashira ALT-803 kamwe chete pavhiki nhatu. Varwere vanogashirawo imwechete yekutarisa inhibitor iyo yavakagashira panguva yavo yekurapa yapfuura. Radiologic kuongorora kuchaitika pakupera kwega kwega kwekurapa kutenderera. Kurapa kunoenderera kusvika kumakore maviri, kana kusvika murwere achinge asangana nechirwere chinofambira mberi kana chepfu isingagamuchirike, abvisa mvumo, kana kana Muongorori achinzwa kuti hazvisisiri mukunakirwa nemurwere kuenderera mberi nekurapwa. Varwere vachateverwa nekuda kwekufambira mberi kwezvirwere, post-Therapies, uye kupona kuburikidza nemwedzi makumi maviri nemana yapfuura manejimendi yedosi yekutanga yekudzidza mushonga.

Nzvimbo: 9 nzvimbo

Chidzidzo cheNKTR-262 Mumubatanidzwa Na NKTR-214 uye Na NKTR-214 Plus Nivolumab mune Varwere Vane Nharaunda Yepamberi kana Metastatic Solid Tumor Malignancies.

Varwere vanogashira intra-tumoral (IT) NKTR-262 mu3-vhiki yekurapa kutenderera. Munguva yeChikamu chekutanga chikamu chekuwedzera kwedosi, NKTR-262 ichasanganiswa nehurongwa hwekutonga bempegaldesleukin. Mushure mekugadzwa kweiyo yakakurudzirwa Phase 2 dose (RP2D) ye NKTR-262, pakati pe6 ne12 varwere vanogona kunyoreswa kuRP2D kuenderera mberi nekuratidzira kuchengetedzeka uye kushivirira chimiro chemubatanidzwa we NKTR 262 pamwe bempegaldesleukin (doublet) kana NKTR 262 plus bempegaldesleukin pamwe chete nivolumab (triplet) muCohorts A uye B, zvichiteerana. Muchikamu chekuwedzera kwechikamu chechipiri chechipiri, varwere vanozobatwa nekaviri kana katatu mune yakadzokororwa / yekumisikidza mamiriro uye ekutanga mitsara yekurapa.

Nzvimbo: 14 nzvimbo

Chidzidzo cheINCMGA00012 muMetastatic Merkel Cell Carcinoma (POD1UM-201)

Chinangwa chechidzidzo ichi ndechekuongorora chiitiko chekiriniki uye chengetedzo yeINCMGA00012 mune vatori vechikamu vane advanced / metastatic Merkel cell carcinoma (MCC).

Nzvimbo: 8 nzvimbo

PEN-221 muSomatostatin Receptor 2 Kuratidzira Yakapfuura Cancers Inosanganisira Neuroendocrine uye Diki Cell Lung Cancers

Protocol PEN-221-001 ndeye yakavhurika-chitaridzi, multicenter Phase 1 / 2a kudzidza kuongorora PEN-221 mune varwere vane SSTR2 vachitaura yakakwira gastroenteropancreatic (GEP) kana mapapu kana thymus kana mamwe mamota eurouroocrocrine kana kenza kadiki kemapapu emapapu kana hombe sero neuroendocrine carcinoma yemapapu.

Nzvimbo: 7 nzvimbo

Chikamu 1/2 Kudzidza kweIn Situ Kubaya pamwe neTremelimumab uye IV Durvalumab Plus PolyICLC mune Zvidzidzo zvine Advanced, Inoyanisika, Biopsy-inowanikwa Cancers

Iyi yakavhurika-label, multicenter Phase 1/2 kudzidza kweiyo CTLA-4 antibody, tremelimumab, uye PD-L1 antibody, durvalumab (MEDI4736), pamwe chete nebundu microenvelo (TME) modulator polyICLC, TLR3 agonist, mune zvidzidzo zvine kenza yemhando yepamusoro, inogona kuyerwa, bhaopsy-inowanikwa.

Nzvimbo: 6 nzvimbo

Intratumoral AST-008 Yakasanganiswa nePembrolizumab muvarwere vane Advanced Solid Tumors

Ichi chikamu 1b / 2, rakavhurika-label, multicenter kuyedzwa kwakagadzirirwa kuongorora kuchengetedzeka, kushivirira, pharmacokinetics, pharmacodynamics uye kutanga kushanda kwejekiseni reSTST-008 majekiseni ega uye pamwe chete neinopinza pembrolizumab mune varwere vane advanced tumors yakasimba. Chikamu 1b cheiyedzo iyi 3 + 3 yedosi yekuwedzera kudzidza kuongorora kuwanda kana kwepakati mwero wero weAS-008 yakapihwa ine yakatarwa dosi yepembrolizumab. Phase 2 iboka rekuwedzera kuti uenderere mberi kuongorora AST-008 yakapihwa musanganiswa ne pembrolizumab mune yakasarudzika vanhu kupa fungidziro yekutanga yekubudirira muvarwere vakambogamuchira uye vasina kupindura anti-PD-1 kana anti-PD-L1 antibody kurapa.

Nzvimbo: 7 nzvimbo

Kwayedza yeIntratumoral Injections yeTTI-621 muVatungamiriri Vakadzokororwa uye Vanokanganisa Mamota Akasimba uye Mycosis Fungoides

Iyi multicenter, yakavhurika-chitaridzi, chikamu 1 chidzidzo chakaitiswa kuyedza intratumoral jekiseni reTTI-621 mune zvidzidzo zvakadzokazve uye zvichiratidzika pari zvino zvinowanika mamota akasimba kana mycosis fungoides. Chidzidzo ichi chichaitwa muzvikamu zviviri zvakasiyana. Chikamu chekutanga chikamu cheDose Escalation uye Chikamu 2 chikamu cheDose Kuwedzera. Chinangwa chechidzidzo ichi ndechekuratidzira chimiro chekuchengetedza kweTTI-621 uye kuona yakaringana muyero uye dhizaini yekuendesa yeTTI-621. Uye zvakare, kuchengetedzwa uye antitumor chiitiko cheTTI-621 chichaongororwa pamwe chete nemamwe anti-cancer agents kana radiation.

Nzvimbo: 5 nzvimbo

Kudzidza kweDP1 Monotherapy uye RP1 mukubatanidza naNivolumab

RPL-001-16 iri Phase 1/2, yakavhurika chitambi, kuwedzera kwedosi uye kuwedzera kiriniki kudzidza kweRP1 yega uye mukubatana nivolumab mune vakuru zvidzidzo zvine advanced uye / kana refractory solid tumors, kuona iyo yakanyanya kubvumidzwa dosi (MTD) uye yakakurudzira Phase 2 dose (RP2D), pamwe nekuongorora kushanda kwekutanga.

Nzvimbo: 6 nzvimbo

Talimogene Laherparepvec ine kana isina Hypofractionated Radiation Therapy Mukurapa Varwere vane Metastatic Melanoma, Merkel Cell Carcinoma, kana Mamwe Mapundu Akaoma.

Ichi chisinganzwisisike chikamu chechipiri cheyedzo inoongorora iyo mhedzisiro yeTalimogene laherparepvec uye kuona kuti inoshanda zvakadii kana pasina hypofractionated radiation kurapwa pakurapa varwere vane ganda melanoma, Merkel cell carcinoma, kana mamwe mamota akasimba akapararira kunzvimbo dzisina kukodzera kubviswa . Mishonga inoshandiswa mu immunotherapy, senge talimogene laherparepvec, inogona kukurudzira immune system kurwisa tumarara maseru. Hypofractionated radiation kurapwa kunounza yakakwira madosi e radiation kurapwa kwenguva pfupi uye inogona kuuraya mamwe maseru emota uye iine mashoma mhedzisiro. Izvo hazvisati zvazivikanwa kana kupa talimogene laherparepvec pamwe kana pasina hypofractionated radiation kurapwa kuchashanda zvirinani pakurapa varwere vane cutaneous melanoma, Merkel cell carcinoma, kana yakasimba mamota.

Nzvimbo: 3 nzvimbo

FT500 seMonotherapy uye muKusanganiswa neImune Checkpoint Inhibitors mune Zvidzidzo zvine Zvipenga Zvakasimba Zvakasimba

FT500 is-off-the-shelf, iPSC-yakatorwa NK cell chigadzirwa icho chinogona kubvarura innate uye adaptive immune, uye ine mukana wekukunda akawanda maitiro e immune checkpoint inhibitor (ICI) kuramba. Iyo yekumberi dhata inopa humbowo hunogombedzera hunotsigira kiriniki kuferefetwa kweFT500 semonotherapy uye mukubatana neICI mune zvidzidzo zvine advanced tumarara yakasimba.

Nzvimbo: 3 nzvimbo

Tacrolimus, Nivolumab, uye Ipilimumab Mukurapa Itsvo Kudyara Vanogamuchira neVakasarudzwa Vasingagadzirisike kana Metastatic Cancers

Ichi chikamu I chiongorori chinoongorora mashandiro anoita tacrolimus, nivolumab, uye ipilimumab mukurapa itsvo kupinza vanogamuchira nekenza isingakwanise kubviswa nekuvhiya (kusinga gadzirisike) kana kupararira kune dzimwe nzvimbo mumuviri (metastatic). Tacrolimus inogona kumisa kukura kwemarara maseru nekuvhara mamwe maenzymes anodiwa kuti sero kukura. Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Kupa tacrolimus, nivolumab, uye ipilimumab zvinogona kushanda zvirinani pakurapa itsvo kupinza vanogamuchira nekenza zvichienzaniswa nekemotherapy, kuvhiyiwa, radiation radiation, kana tarisiro yekurapa.

Nzvimbo: 2 nzvimbo

Nivolumab uye Ipilimumab ine kana isina Stereotactic Muviri Radiation Therapy Mukurapa Varwere neRecurrent kana Stage IV Merkel Cell Cancer.

Ichi chisinganzwisisike chikamu chechipiri cheyedzo yekuongorora kuti nivolumab uye ipilimumab ine kana isina stereotactic muviri radiation radiation inoshanda pakurapa varwere vane Merkel cell cancer yakadzoka kana iri danho IV. Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Stereotactic muviri radiation kurapwa inoshandisa yakakosha michina kumisikidza murwere uye kuendesa radiation kune mamota ane akakwana kunyatsoita. Iyi nzira inogona kuuraya tumarara maseru ane mashoma masosi pane ipfupi nguva uye anokonzeresa kukuvara kudiki kune chaiwo tishu. Kupa nivolumab uye ipilimumab ine kana isina stereotactic muviri radiation radiation inogona kushanda zvirinani pakurapa varwere vane Merkel cell cancer.

Nzvimbo: 2 nzvimbo

Pembrolizumab uye Radiation Therapy yeKurapa kweMetastatic Merkel Cell Carcinoma

Iyi chikamu II kuyedzwa kunoongorora mhedzisiro uye kuti pembrolizumab uye radiation radiation inoshanda sei pakurapa varwere vane Merkel cell carcinoma yakapararira kune dzimwe nzvimbo mumuviri (metastatic). Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Radiation kurapa kunoshandisa yakakwira simba x-rays kuuraya mamota maseru uye kudzikira matumha. Kupa pembrolizumab uye radiation kurapwa kunogona kuwedzera kubatsirwa kwepembrolizumab.

Nzvimbo: Stanford Cancer Institute Palo Alto, Palo Alto, California

Chidzidzo cheLY3434172, PD-1 uye PD-L1 Bispecific Antibody, muAdvanced Cancer

Chinangwa chikuru cheichi chidzidzo ndechekuongorora kuchengetedzeka uye kusashivirira kwechirwere chekudzidza LY3434172, PD-1 / PD-L1 bispecific antibody, muvatori vechikamu vane mamota akasimba akakwira.

Nzvimbo: MD Anderson Cancer Center, Houston, Texas

Cell Therapy (Tumor Inopindirira maLymphocyte) ekurapa Kwenharaunda Yepamberi, Metastatic, kana Dzokororo Kenza Yakasimba.

Ichi chikamu chechipiri cheyedzo inoongorora mashandiro anoita maseru kurapa (ane bundu rinopinza ma lymphocyte) anoshanda ekurapa kenza yakasimba iyo yakapararira kumatishu ari pedyo kana lymph node (yemuno yakasimukira), yapararira kune zvimwe zvikamu zvemuviri (metastatic), kana ine dzoka (dzokororo). Kuedzwa uku kunosanganisira kutora masero anonzi maLymphocyte (rudzi rwechena reropa) kubva pamamota evarwere, achiakurira murabhoritari muhuwandu, uyezve ndokudzorera maseru kumurwere. Aya maseru anonzi tumarara tinopinda ma lymphocyte uye kurapwa kwacho kunodaidzwa kunzi cell cell. Kupa chemotherapy madhiragi maseru asati adzvinyirira immune system kuti ivandudze mikana yekuti maseru anorwisa bundu anokwanisa kurarama mumuviri. Kupa aldesleukin mushure mekutarisirwa kwesero kunogona kubatsira bundu rinorwisa maseru kugara mupenyu kwenguva refu.

Nzvimbo: Yunivhesiti yePittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Nivolumab uye Radiation Therapy kana Ipilimumab seAdjuvant Therapy Mukurapa Varwere neMerkel Cell Cancer

Ichi chikamu I muyedzo unoongorora mhedzisiro uye mashandiro anoita nivolumab painopihwa pamwechete ne radiation radiation kana ipilimumab seAdjuvant Therap pakurapa varwere vane Merkel cell cancer. Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Radiation Therapy inoshandisa yakakwira simba x-rays, gamma mwaranzi, neutron, proton kana zvimwewo sosi kuuraya tumarara maseru uye kudzora tumarara. Kupa nivolumab ne radiation therapy kana ipilimumab mushure mekuvhiyiwa kunogona kuuraya chero akasara mamota maseru.

Nzvimbo: Ohio State University Yakakwana Cancer Center, Columbus, Ohio

Pembrolizumab (MK-3475) seYokutanga-mutsara Therapy yeAdvanced Merkel Cell Carcinoma (MK-3475-913)

Iri ruoko-rwakavhurika, rakavhurika-label, multicenter, kugona, uye chengetedzo kudzidza kwepembrolizumab muvakuru uye vana vatori vechikamu nevaya vasina kurapwa kurapwa advanced Merkel Cell Carcinoma (MCC). Chinangwa chekutanga chekuyedza ndechekuongorora muyero wekupindura, sekuyedzwa nekupofumadza yakazvimirira yepakati ongororo paMhinduro Yekuongorora Maitiro muSolid Tumors vhezheni 1.1 (RECIST 1.1) yakagadziridzwa kuteedzera akanyanya gumi maronda maronda uye akanyanya e5 maronda maronda. Nhengo imwe neimwe, zvichitevera manejimendi pembrolizumab.

Nzvimbo: Laura naIsaac Perlmutter Cancer Center kuNYU Langone, New York, New York

Gene-Modified Immune Seli (FH-MCVA2TCR) Mukurapa Varwere vane Metastatic kana Isingaonekwe Merkel Cell Cancer

Iyi chikamu I / II kuyedza inoongorora mhedzisiro yemagineti-akachinjika immune maseru (FH-MCVA2TCR) uye kuona mashandiro avanoshanda pakurapa varwere vane Merkel kenza yesero yakapararira kune dzimwe nhengo dzomuviri (metastatic) kana isingakwanise kubviswa nekuvhiyiwa (kusingachinjike). Kuisa geni rakagadzirwa murabhoritari mumasero ekudzivirira muviri kunogona kuvandudza kugona kwemuviri kurwisa kenza yemusero yeMerkel.

Nzvimbo: Fred Hutch / Yunivhesiti yeWashington Cancer Consortium, Seattle, Washington

YeKuchengetedza uye Kushivirira Kudzidza kweINCAGN02390 mu Sarudza Advanced Malignancies

Chinangwa chechidzidzo ichi ndechekuona kuchengetedzeka, kushivirira, uye kushanda kwekutanga kweINCAGN02390 muvatori vechikamu vane zvakasarudzika malignancies.

Nzvimbo: Hackensack University Medical Center, Hackensack, New Jersey

Abexinostat uye Pembrolizumab Mukurapa Varwere vane MSI-Yakakwira Yemunharaunda Yakawedzera kana Metastatic Solid Tumors.

Ichi chikamu I muyedzo unoongorora yakanakisa dhosi uye mhedzisiro mhedzisiro yeabexinostat uye kuti inoshanda zvakadii kupihwa pamwe chete ne pembrolizumab mukurapa varwere vane microsatellite kusagadzikana (MSI) mamota akasimba akapararira kumaturu ari pedyo kana ma lymph node (enzvimbo yepamusoro) kana dzimwe nzvimbo mumuviri (metastatic). Abexinostat inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzymes anodiwa kuti sero kukura. Immunotherapy ine monoclonal antibodies, senge pembrolizumab, inogona kubatsira immune immune kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Kupa abexinostat uye pembrolizumab kunogona kushanda zvirinani pakurapa varwere vane mamota akasimba.

Nzvimbo: UCSF Medical Center-Gomo reZion, San Francisco, California

1 2 Inotevera>